Furthermore, when TKI-sensitive CML cells are treated with TKIs, such as dasatinib or nilotinib, MLL2 expression, which can increase p21 expression, is induced while the expression of CDK2, CDK4, and cyclin B1 is attenuated, resulting in a higher rate of cell death [154]. Here, KMT2D is linked to chronic myelogenous leukemia, BCR-ABL1 positive.